Related Experiment Video
Updated: Jun 21, 2025
06:46
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
15.8K
Sertraline Alleviates Chronic Prostatitis by Regulating the TRPV1 Channel
Yongfeng Lao1,2, Yanan Bai1,2, Xin Guan1,2
1Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Journal of Inflammation Research
|July 9, 2024
Summary
Sertraline demonstrates anti-inflammatory effects for chronic prostatitis (CP) by targeting the TRPV1 channel, reducing pain and improving symptoms in mouse models. This suggests sertraline may be a valuable complementary treatment for CP.
Area of Science:
- Pharmacology
- Urology
- Molecular Biology
Background:
- Chronic prostatitis (CP) is a condition with unclear treatment mechanisms.
- Sertraline is widely used for CP, but its underlying mechanisms require elucidation.
Purpose of the Study:
- To explore the molecular mechanisms of sertraline in treating chronic prostatitis (CP).
- To investigate the role of the TRPV1 channel in sertraline's therapeutic effects on CP.
Main Methods:
- Network pharmacology identified key targets, including TRPV1.
- In vitro (RWPE-1 cells) and in vivo (EAP mice) models were used to assess sertraline's effects.
- Assays included cell proliferation, apoptosis, ROS and calcium concentration detection, pain response, and histopathology.
Main Results:
- Sertraline inhibited proliferation, reduced ROS, and promoted apoptosis in LPS-induced cells, with direct binding to TRPV1 confirmed.
- Sertraline treatment decreased pain, depressive symptoms, and prostate inflammation in EAP mice, downregulating TRPV1 expression.
- TRPV1 activation reversed sertraline's effects, confirming TRPV1's central role.
Conclusions:
- Sertraline exhibits anti-inflammatory effects in CP models by regulating the TRPV1 channel.
- Sertraline may serve as a complementary anti-inflammatory agent for chronic prostatitis.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
244
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
244
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
358
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
358
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:23Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215
01:21G-protein Coupled Receptors
117.9K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
117.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269